Differential genomic profiling of the progesterone receptor (PR) negative and estrogen receptor (ER) low metastatic breast cancer subtypes through circulating tumor DNA: A TNBC-like disease subtype?

被引：0
|
作者：
Gerratana, Lorenzo
Davis, Andrew A.
Foffano, Lorenzo
Reduzzi, Carolina
Podany, Emily L.
Medford, Arielle J.
Clifton, Katherine
Velimirovic, Marko
Putur, Annika
Munoz-Arcos, Laura Sofia
Pontolillo, Letizia
Tapiavala, Shaili
Molteni, Elisabetta
Nicolo, Eleonora
Gradishar, William John
Ma, Cynthia X.
Andreopoulou, Eleni
Puglisi, Fabio
Bardia, Aditya
Cristofanilli, Massimo
机构：
[1] Univ Udine, Dept Med DMED, Aviano, Italy
[2] Washington Univ St Louis, St Louis, MO USA
[3] Univ Udine, Udine, Italy
[4] Weill Cornell Med, New York, NY USA
[5] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[6] Washington Univ, Sch Med, St Louis, MO USA
[7] Cleveland Clin, Cleveland, OH USA
[8] Massachusetts Gen Hosp, Boston, MA USA
[9] Northwestern Univ, Div Hematol & Oncol, Dept Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[10] Univ Udine, Dept Med DAME, Udine, Italy
[11] Ctr Riferimento Oncol Aviano CRO, Dipartimento Oncol Medica, IRCCS, Udine, Italy
[12] UCLA Hlth Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1039
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Retrospective analysis of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), Ki67 changes and their clinical significance between primary breast cancer and metastatic tumors
    Qi, Gaoxiu
    Zhang, Xin
    Gai, Xiaoying
    Yan, Xiong
    PEERJ, 2024, 12
  • [42] NOLUS: a predictive model to identify Basal-like and HER2-enriched intrinsic subtypes based on estrogen receptor (ER), progesterone receptor (PR) and Ki67 immunohistochemistry (IHC) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
    Pascual, T.
    Martin, M.
    Pare, L.
    Alba, E.
    Rodriguez-Lescure, A.
    Perrone, G.
    Cortes, J.
    Morales, S.
    Lluch, A.
    Urruticoechea, A.
    Galvan, P.
    Rodriguez, A.
    Chic, N.
    Righi, D.
    Cejalvo, J. M.
    Tonini, G.
    Adamo, B.
    Vidal, M.
    Munoz, M.
    Prat, A.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S138 - S138
  • [43] Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells
    Bartucci, M
    Morelli, C
    Mauro, L
    Ando', S
    Surmacz, E
    CANCER RESEARCH, 2001, 61 (18) : 6747 - 6754
  • [44] Triple fluorescence analysis of estrogen receptor alpha (ER) and ErbB2 status of circulating tumor cells (CTC) in breast cancer: from cell models to metastatic patients
    Bock, Carolin
    Kuhn, Christina
    Majunke, Leonie
    Hofmann, Simone
    Jaeger, Bernadette
    Theil, Conrad
    Jeschke, Udo
    Rack, Brigitte
    Doisneau-Sixou, Sophie F.
    CANCER RESEARCH, 2012, 72
  • [45] Circulating tumor DNA dynamics in acelERA Breast Cancer: a Phase II study of giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer
    Collier, Ann
    Bardia, Aditya
    Sohn, Joo Hyuk
    Lim, Elgene
    Chavez, Marianna
    Martin, Miguel
    Martinalbo, Jorge
    Perez-Moreno, Pablo
    Moore, Heather
    CANCER RESEARCH, 2024, 84 (09)
  • [46] The combined blood analysis of cell-free DNA and genomic DNA of circulating tumor cells reveals additive value in hormone receptor-positive, HER2-negative metastatic breast cancer patients
    Keup, Corinna
    Bittner, Ann-Kathrin
    Hoffmann, Oliver
    Tewes, Mitra
    Storbeck, Markus
    Hahn, Peter
    Hauch, Siegfried
    Sprenger-Haussels, Markus
    Kimmig, Rainer
    Kasimir-Bauer, Sabine
    CANCER RESEARCH, 2020, 80 (04)
  • [47] Circulating tumor DNA (ctDNA) monitoring of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) high risk breast cancer during adjuvant endocrine therapy
    Pusztai, Lajos
    Kalashnikova, Ekaterina
    Hobbs, Evthokia
    Brown-Glaberman, Ursa
    Mita, Monica
    Klein, Paula
    Yan, Fengting
    Ehsani, Sima
    Razaq, Wajeeha
    Stopeck, Alison
    Bhave, Manali
    Loch, Michelle
    Sardesai, Sagar
    Torres, Evanthia Roussos
    Burkard, Mark
    Okubanjo, Femi
    Gauthier, Eric
    Rodriguez, Angel
    Liu, Minetta
    Kabos, Peter
    CANCER RESEARCH, 2024, 84 (09)
  • [48] Molecular analysis of cancer tissue, circulating tumor cells (CTC) and cell-free plasma tumor DNA (ptDNA) suggests variable mechanisms of resistance to endocrine therapy (ET) in estrogen receptor (ER) positive metastatic breast cancer (MBC)
    Paoletti, C.
    Aung, K.
    Cannel, E. M.
    Darga, E. P.
    Chu, D.
    Kidwell, K. M.
    Thomas, D. G.
    Tokudome, N.
    Brown, M. E.
    McNutt, L. M.
    Gersch, C.
    Schott, A. F.
    Park, B. H.
    Robinson, D. R.
    Chinnaiyan, A. M.
    Rae, J. M.
    Hayes, D. F.
    CANCER RESEARCH, 2016, 76
  • [49] Estrogen receptor β2 (ERβ2)-mediated upregulation of hsa_circ_0000732 promotes tumor progression via sponging microRNA-1184 in triple-negative breast cancer (TNBC)
    Di Chen
    Meng Wang
    Hanchao Zhang
    Siwei Zhou
    Chengyu Luo
    Inflammation Research, 2022, 71 : 255 - 266
  • [50] Estrogen receptor β2 (ERβ2)-mediated upregulation of hsa_circ_0000732 promotes tumor progression via sponging microRNA-1184 in triple-negative breast cancer (TNBC)
    Chen, Di
    Wang, Meng
    Zhang, Hanchao
    Zhou, Siwei
    Luo, Chengyu
    INFLAMMATION RESEARCH, 2022, 71 (02) : 255 - 266
12345